Coccidioidomycosis (Valley fever)

Overview

Coccidioidomycosis begins when airborne arthroconidia from Coccidioides-contaminated soil are inhaled. The fungi are endemic in parts of the southwestern United States and in areas of Mexico, Central America and South America. Infection is generally acquired from the environment rather than from another person. ^{[1] [2]}

Inhaled spores transform into spherules in lung tissue and provoke an immune response. Many infections are controlled without recognized symptoms. Symptomatic primary pulmonary disease can resemble bacterial pneumonia, while persistent or impaired immune control can lead to cavities, chronic pulmonary disease or dissemination through the bloodstream. ^{[1] [2]}

Valley fever should be considered in compatible pneumonia when a patient lives in or traveled through an endemic area, particularly when symptoms do not improve as expected with antibacterial therapy. Geography is therefore part of the diagnostic test. A normal chest presentation outside a recognized endemic area lowers, but does not eliminate, likelihood because travel and expanding geographic recognition matter. ^{[1] [2] [3]}

Symptoms and warning signs

Symptoms usually begin one to three weeks after exposure and can include fatigue, cough, fever, shortness of breath, headache, night sweats, muscle or joint aches and rash. Erythema nodosum can occur. Fatigue may be prolonged even when pulmonary symptoms improve. Many infected people never develop a recognized symptomatic illness. ^{[1] [2]}

Severe breathing difficulty, hypoxemia, confusion, signs of sepsis or neurologic symptoms require urgent care. Persistent severe headache, neck stiffness or focal neurologic symptoms raise concern for coccidioidal meningitis. Immunocompromised patients and pregnant patients in certain stages require a lower threshold for specialist evaluation. ^{[1] [2]}

Diagnosis

Serologic antibody testing for Coccidioides IgM and IgG is the most common initial diagnostic approach. CDC’s testing algorithm supports enzyme immunoassay with confirmatory immunodiffusion or complement fixation depending on availability and results. Early tests can be negative, so repeat testing may be appropriate when clinical suspicion remains high. ^{[1] [2]}

Culture, histopathology and microscopy can establish diagnosis in selected patients, particularly severe or extrapulmonary disease. Respiratory culture requires biosafety precautions because laboratory propagation of Coccidioides is hazardous. Complement-fixation titers can support severity assessment and longitudinal follow-up but should not be interpreted in isolation. ^{[1] [2] [3]}

Bacterial community-acquired pneumonia, tuberculosis, histoplasmosis, other fungal infections, malignancy and inflammatory lung disease can resemble Valley fever. In endemic areas, coccidioidomycosis should be considered before repeated antibacterial courses when pneumonia does not behave as expected. ^{[2] [3]}

Causes, risk factors and clinical context

Anyone exposed in an endemic region can be infected. Risk of severe or disseminated disease is higher with substantial immune suppression and certain host factors; pregnancy, particularly later pregnancy and the early postpartum period, can alter risk. High dust exposure during construction, farming, military training or dust storms can increase environmental exposure. ^{[1] [2]}

Primary pulmonary disease is often self-limited. CDC notes that approximately 40% of infections develop symptoms, while 5–10% of patients develop complications or chronic pulmonary disease and disseminated disease is estimated in about 1% overall. Recovery from fatigue can take weeks or months even without progressive infection. ^{[1] [2] [3]}

Complications and why the diagnosis matters

Complications include pulmonary nodules or cavities, chronic fibrocavitary lung disease and dissemination to skin, bone, joints or meninges. Coccidioidal meningitis is a particularly serious complication and generally requires long-term specialist therapy. Severe diffuse pulmonary disease can occur in markedly immunocompromised people. ^{[1] [2]}

Most immunocompetent people with uncomplicated primary disease recover. Prognosis depends strongly on disease site and host risk. Disseminated meningitis and severe immunocompromised disease can be life threatening and require prolonged therapy and follow-up. ^{[1] [2] [3]}

Treatment and management

Not every uncomplicated infection requires antifungal treatment. Clinicians weigh symptom severity, duration, host risk and evidence of progression. When therapy is indicated, oral azoles such as fluconazole are commonly used, while severe pulmonary or disseminated disease may require amphotericin B followed by azole therapy. ^{[1] [2]}

Supportive care includes hydration, rest, fever and pain control and monitoring of respiratory status. People with prolonged fatigue benefit from a graded recovery plan rather than assuming persistent tiredness means treatment failure. Pulmonary nodules or cavities discovered after infection require evaluation to distinguish residual disease from malignancy or another cause. ^{[1] [2] [3]}

Antifungal drugs have important liver, pregnancy and drug-interaction considerations. Therapy should be clinician directed, especially in pregnancy or with immunosuppression. Repeated antibacterial treatment does not treat Coccidioides and can delay the correct diagnosis. ^{[1] [2]}

Follow-up, recovery and prevention

Follow-up can include symptoms, chest imaging and serologic titers depending on disease severity. Worsening respiratory symptoms, rising titers or new extrapulmonary symptoms prompt reassessment. Patients with meningitis, major immune suppression or disseminated disease require long-term specialist monitoring. ^{[1] [2]}

There is no licensed vaccine. Completely avoiding airborne spores is difficult in endemic regions. People at high risk can reduce exposure to heavy dust, use appropriate workplace controls and follow public-health advice during dust-producing activities, but routine masks cannot guarantee prevention. ^{[1] [2] [3]}

Special situations and care pathway

Pregnancy requires specialist management because disease severity and antifungal safety vary by trimester. Transplant recipients and people receiving potent immunosuppressive therapy may need screening or preventive strategies in highly endemic areas according to specialist protocols. Disseminated disease can occur even without dramatic lung symptoms. ^{[1] [2] [3]}

Recognize compatible pneumonia plus endemic exposure, order appropriate serology, repeat or confirm testing when needed, determine whether disease is uncomplicated or high risk, and choose observation versus antifungal therapy accordingly. Investigate neurologic, bone, joint or skin symptoms for dissemination. ^{[1] [2]}

When to seek urgent medical care

Seek urgent care for severe shortness of breath, low oxygen levels, confusion, severe systemic illness or persistent severe headache and neck stiffness. Immunocompromised patients with suspected Valley fever should contact their clinician promptly. ^{[1] [2]}

Sources

1. CDC — Clinical Overview of Valley Fever
2. CDC — Testing Algorithm for Coccidioidomycosis
3. CDC — About Valley Fever

This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.